ISTA Pharmaceuticals, Inc. 

(Public, NASDAQ:ISTA)   Watch this stock   
Find more results for ISTA
Nov 3, 2009
Q3 2009 Earnings Conference Call - Webcast
Nov 3, 2009
Q3 2009 Earnings Release
Oct 27, 2009
BIOCOM Investor Conference
Sep 16, 2009
BioCentury `NewsMakers in the Biotech Industry` Clear Route Investment Conference - Webcast
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin -2.87% -36.92%
Operating margin 16.40% -29.86%
EBITD margin - -28.61%
Return on average assets - -39.74%
Return on average equity - -
Employees 225 -

Address

15295 Alton Parkway
Irvine, CA 92618
United States - Map
+1-949-7886000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

ISTA Pharmaceuticals, Inc. discussions

  View all discussions »

Description

ISTA Pharmaceuticals, Inc. is an ophthalmic pharmaceutical company with products and product candidates for the treatment of inflammation, ocular pain, glaucoma, allergy and dry eye. The Company has three products available for sale in the United States: Xibrom, (bromfenac ophthalmic solution) for the treatment of inflammation and pain following cataract surgery, Istalol, (timolol maleate ophthalmic solution) for the treatment of glaucoma, and Vitrase (hyaluronidase for injection) for use as a spreading agent. The Company also has several product candidates in various stages of development. These include a strong steroid product candidate to treat ocular inflammation, iganidipine to enhance ocular nerve blood flow and a new formulation of latanoprost for the treatment of glaucoma.

Officers and directors

Richard C. Williams
Chairman of the Board
Age: 65
Bio & Compensation - Reuters
Vicente Anido Jr., Ph.D.
President, Chief Executive Officer, Director
Age: 56
Bio & Compensation - Reuters
Lauren P. Silvernail
Chief Financial Officer, Vice President - Corporate Development, Chief Accounting Officer
Age: 50
Bio & Compensation - Reuters
Kirk McMullin
Vice President - Operations
Portrait. Age: 55
Bio & Compensation - Reuters
Thomas A. Mitro
Vice President - Sales and Marketing
Age: 51
Bio & Compensation - Reuters
Kathleen McGinley
Vice President - Human Resources and Corporate Services
Portrait. Age: 59
Bio & Compensation - Reuters
Marvin J. Garrett
Vice President - Regulatory Affairs, Quality & Compliance
Age: 58
Bio & Compensation - Reuters
Timothy R. McNamara
Vice President - Clinical Research and Medical Affairs
Age: 53
Bio & Compensation - Reuters
Benjamin F. McGraw III
Director
Age: 59
Bio & Compensation - Reuters
Wayne I. Roe
Director
Age: 58
Bio & Compensation - Reuters